Zhongchao (NASDAQ:ZCMD – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings lowered Zhongchao from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 25th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company has a consensus rating of “Sell”.
Read Our Latest Report on Zhongchao
Zhongchao Stock Down 7.3%
Shares of NASDAQ:ZCMD opened at $1.02 on Friday. The stock’s 50-day moving average price is $1.59 and its 200-day moving average price is $183.68. Zhongchao has a 12-month low of $1.02 and a 12-month high of $1,443.36.
About Zhongchao
Zhongchao Inc (NASDAQ: ZCMD) is a China-based healthcare services company focused on medical education and patient management. Through its operating subsidiaries, the company provides services intended to support healthcare professionals, patients and pharmaceutical or medical-product companies, with an emphasis on oncology and other chronic disease areas.
Zhongchao’s medical education activities have included online and offline educational programs, academic conferences, seminars and other professional training initiatives for physicians and healthcare providers.
Featured Articles
- Five stocks we like better than Zhongchao
- MarketBeat Week in Review – 10/26 – 10/30
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
Receive News & Ratings for Zhongchao Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zhongchao and related companies with MarketBeat.com's FREE daily email newsletter.
